NightstaRx Commences first Phase I/II Gene Therapy Clinical Trial … – Business Wire (press release)
|
NightstaRx Commences first Phase I/II Gene Therapy Clinical Trial …
Business Wire (press release) NightstaRx Ltd (“Nightstar”), a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, tod. |
